Reliance’s Strand Life Sciences Secures Patent for Cancer Detection

The Bengaluru-based genomics firm has been granted a key patent for technology underpinning its early-stage cancer screening capabilities.

BENGALURU — Strand Life Sciences, a subsidiary of Reliance Industries Limited, has secured a significant patent for its proprietary technology designed for the early detection of cancer. The development represents a milestone in the company’s ongoing efforts to scale its "CancerSpot" platform, a blood-based screening test that uses advanced genomic sequencing to identify tumor-derived DNA fragments.

The patent, granted for its innovative process in identifying DNA methylation signatures, reinforces the company's competitive position in the global diagnostics market. By accurately detecting early-stage cancer signals through a minimally invasive liquid biopsy, the technology aims to shift the focus of oncology from late-stage intervention to proactive, routine screening.

Precision Through Genomic Innovation

Strand Life Sciences has been at the forefront of combining bioinformatics with clinical genomics for over two decades. The newly patented technology functions by analyzing cell-free DNA in a blood sample to detect specific methylation patterns—chemical markers that act as fingerprints for various types of cancer.

According to company technical disclosures, the patented process allows for high sensitivity in identifying tumors, even when they are present in very low concentrations within the bloodstream. This "fragmentomics" approach is critical for detecting Stage I and Stage II cancers, where traditional diagnostic methods—such as imaging or tissue biopsies—often lack the necessary reach or convenience.

Impact on Healthcare Accessibility

The commercialization of this patented technology is a central pillar of Reliance Industries' broader healthcare vision. Speaking on the company’s long-term objectives, officials have emphasized the need to democratize precision diagnostics in India.

"Early warning is the key to battle cancer—and win it," said Dr. Ramesh Hariharan, CEO and Co-Founder of Strand Life Sciences. The company has stated its intent to make these advanced screening tools increasingly affordable, with plans to reduce testing costs significantly over the coming years. By moving cancer detection into the realm of routine blood work, Strand aims to alleviate the diagnostic burden on families and healthcare systems alike.

Official Sources and Regulatory Standing

The patent grant adds to Strand Life Sciences' robust intellectual property portfolio, which currently supports a wide array of clinical diagnostics, including hereditary cancer panels, liquid biopsies, and multiomics research services. The company operates out of its state-of-the-art Genomics Diagnostics & Research Centre in Bengaluru, a 33,000-square-foot facility inaugurated to accelerate the development of life-saving diagnostics.

Official company filings indicate that Strand’s CancerSpot signatures have been validated against large Indian cohorts, with the company noting that its proprietary algorithms remain robust across diverse ethnic backgrounds, ensuring global applicability.

Why It Matters

For the medical community, the broader patenting of these methylation-based detection methods signifies a shift toward more reliable, non-invasive oncology screening. Patients stand to benefit from a "diagnostic odyssey" reduction, where early detection can lead to significantly better survival rates and lower treatment costs. For investors, the move signals the growing commercial viability of Reliance’s life sciences vertical, which is increasingly utilizing AI and machine learning to interpret complex genomic data.

Key Facts at a Glance

• Technology Focus: Patented DNA methylation signature analysis for early-stage cancer detection.

• Methodology: Liquid biopsy (blood-based) requiring a simple sample draw.

• Cancer Coverage: Designed to detect signals for 10 common cancers, including colorectal, breast, lung, and pancreatic.

• Facility: Operations are centered at the company’s dedicated Genomics Diagnostics & Research Centre in Bengaluru.

• Parent Company: Strand Life Sciences is a subsidiary of Reliance Industries Limited.

Frequently Asked Questions

What does this patent cover?

The patent covers the proprietary genome sequencing and analysis process used to identify specific cancer-linked DNA methylation signatures in the blood.

How does this test differ from standard cancer screening?

Unlike traditional screenings that may require imaging or invasive biopsies, this test is a simple blood draw that screens for multiple cancer types simultaneously using genomic data.

Is this test intended for diagnosis or screening?

As per the company’s clinical guidelines, the test is designed for screening and early warning; positive results should be followed by confirmatory diagnostic procedures as advised by a physician.

Source: Strand Life Sciences Official Pressroom, Reliance Industries Limited (RIL) Corporate Filings, BioSpectrum India